ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0390

Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients

Sonia Pastor Navarro1, Marta Ibáñez Martínez1, Olga Compán Fernández1, Belén Miguel Ibáñez1, Olga Martínez González1, Cristina Hidalgo Calleja1, Ana Isabel Turrión Nieves1, Susana Gómez Castro2 and Carlos Montilla Morales1, 1Hospital Universitario de Salamanca, Salamanca, Spain, 2Hospital Universitario Salamanca, Salamanca, Spain

Meeting: ACR Convergence 2022

Keywords: Anxiety, COVID-19, Fatigue, Psoriatic arthritis, quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Symptomatic onset long after recovery from the acute phase of COVID-19 infection has been reported by the population. Currently, it is not known how certain “Long Covid” symptoms affect a population of patients with psoriatic arthritis (PsA).

The objective is to assess the affectation of the “Long Covid Syndrome” in the clinical and emotional condition of a group of patients with PsA.

Methods: A prospective observational study of thirty-two patients diagnosed with PsA by the CASPAR criteria has been carried out. All those who had constituted a “confirmed case” of COVID-19 were selected following the Raveendran criteria.

Fatigue was assessed in this group of patients using the FACIT-F (Functional Assessment of Chronic Illness Therapy- Fatigue) self-administered questionnaire. The existence of anxiety or depression was obtained with the HADS-A (Hospital Anxiety and Depression Scale- anxiety) and HADS-D (Hospital Anxiety and Depression Scale- depression) questionnaires. Sleep quality disturbance was examined using the ISI (Insomnia Severity Index) questionnaire. All questionnaires were applied simultaneously in person or electronically in two different occasions to each of the individuals, one before contagion and another four weeks after the COVID-19 infection had been resolved.

Results: Patients were predominantly male with a mean age of 53 years and PsA disease duration of 13.2 years, with a standard deviation (SD) of 9 and 13.2 years respectively. PsA patients had a mean fatigue score of 35.21 (SD 11.43). The average of fatigue in that same group before suffering from COVID-19 was 39.56 (SD 10.57) (p=0.001). No relationship was found in the correlation of fatigue with the rest of the parameters. 18.75% of patients showed initial anxiety and 6.25% depression. The same group of patients after COVID-19 showed rates of anxiety and depression of 43.75% and 14.29%, respectively. 12.5% of patients with PsA had insomnia prior to COVID-19, which caused a 43.75% increase in sleep disturbances in the same study group (Table 1).

Regarding the relation between changes in fatigue, anxiety, depression and sleep quality and baseline characteristics, an increase in anxiety and a worsening in sleep quality were observed after COVID-19, which were related to baseline anxiety and baseline sleep quality respectively. No differences were found in the other parameters. No differences were found between increased fatigue and baseline variables (Table 2).

Finally, no significant differences were found between changes in fatigue, anxiety, depression and sleep quality and COVID-19 clinical characteristics.

Conclusion: COVID-19 influences fatigue, sleep, anxiety and depression. Except for anxiety and sleep quality, this increase is not due to presence of previous features or the characteristics of COVID-19 infection.

Supporting image 1

Table 1: Differences between fatigue, anxiety, depression and sleep before and after COVID_19 disease.

Supporting image 2

Table 2: Correlation between baseline characteristics and different scales.
*p: p-value, BMI: body mass index, M/F: male/female, Y/N: yes/no, DMARDs-c: conventional disease-modifying antirheumatic drug, DMARDs-b: biological disease-modifying antirheumatic drug.


Disclosures: S. Pastor Navarro, None; M. Ibáñez Martínez, None; O. Compán Fernández, None; B. Miguel Ibáñez, None; O. Martínez González, None; C. Hidalgo Calleja, None; A. Turrión Nieves, None; S. Gómez Castro, None; C. Montilla Morales, None.

To cite this abstract in AMA style:

Pastor Navarro S, Ibáñez Martínez M, Compán Fernández O, Miguel Ibáñez B, Martínez González O, Hidalgo Calleja C, Turrión Nieves A, Gómez Castro S, Montilla Morales C. Persistent Post-Covid Symptoms in Psoriatic Arthritis Patients [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/persistent-post-covid-symptoms-in-psoriatic-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/persistent-post-covid-symptoms-in-psoriatic-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology